Want to see OPRX full AI Analyst Report?
OPRX Stock Chart & Stats
$7.86
$0.11(1.76%)
At close: 4:00 PM EDT
$7.86
$0.11(1.76%)
Day’s Range― - ―
52-Week Range$4.54 - $22.25
Previous CloseN/A
Volume41.31K
Average Volume (3M)153.66K
Market Cap
$164.63M
Enterprise Value$102.84M
Total Cash (Recent Filing)$24.10M
Total Debt (Recent Filing)$19.48M
Price to Earnings (P/E)36.7
Beta2.09
Next Earnings
Nov 10, 2026EPS Estimate
0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.24
Shares Outstanding18,835,950
10 Day Avg. Volume146,742
30 Day Avg. Volume153,659
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)1.77
Price to Sales (P/S)2.08
P/FCF Ratio12.19
Enterprise Value/Market Cap0.62
Enterprise Value/Revenue1.04
Enterprise Value/Gross Profit1.44
Enterprise Value/Ebitda6.53
Forecast
1Y Price Target
$13.00Price Target Upside65.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.9
Revenue Forecast (FY)$96.49M
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation And Debt ReductionStrong operating cash flow provides internal funding for operations and investment, while rapid debt paydown reduces interest and refinancing pressure. Together, these improvements strengthen financial flexibility and give management more capacity to withstand volatility or pursue growth initiatives.
Product Innovation And Platform ExpansionNew EHR integration, audience-building capabilities, and real-time copay activation broaden the platform’s usefulness to pharmaceutical customers. Rising DAP adoption suggests increasing engagement with these tools, supporting competitive relevance and future customer expansion.
Improving Profitability And Recurring Revenue MixGrowth in AI-enabled subscription revenue can make the business mix more recurring and predictable than campaign-driven activity alone. Strong gross margins and ongoing margin optimization also support durable earnings conversion if the company stabilizes its top line.
Bears Say
Sharp Revenue Decline And Customer ConcentrationA 30% quarterly revenue contraction tied to a few large accounts shows that customer concentration can materially affect the company’s results. Dependence on major pharmaceutical customers makes revenue less resilient and raises the risk of prolonged volatility.
Weak Retention And Uncertain Revenue VisibilityRetention below 100% indicates that existing customer spending is contracting rather than expanding, which can weaken the recurring revenue base. Uncertain timing and mix for second-half sales further complicate planning and increase execution risk despite reaffirmed guidance.
Profitability Remains Vulnerable Under Demand PressureThe return to a GAAP loss and year-over-year EBITDA decline indicate that recent demand weakness is affecting operating performance even as cost controls support adjusted profitability. Sustained softness could pressure margins and reduce the pace of cash generation.
OptimizeRx News
OPRX FAQ
What was OptimizeRx Corporation’s price range in the past 12 months?
OptimizeRx Corporation lowest stock price was $4.54 and its highest was $22.25 in the past 12 months.
What is OptimizeRx Corporation’s market cap?
OptimizeRx Corporation’s market cap is $164.63M.
When is OptimizeRx Corporation’s upcoming earnings report date?
OptimizeRx Corporation’s upcoming earnings report date is Nov 10, 2026 which is in 20 days.
How were OptimizeRx Corporation’s earnings last quarter?
OptimizeRx Corporation released its earnings results on Aug 12, 2026. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.111 by $0.049.
Is OptimizeRx Corporation overvalued?
According to Wall Street analysts OptimizeRx Corporation’s price is currently Undervalued.
Does OptimizeRx Corporation pay dividends?
OptimizeRx Corporation does not currently pay dividends.
What is OptimizeRx Corporation’s EPS estimate?
OptimizeRx Corporation’s EPS estimate is 0.17.
How many shares outstanding does OptimizeRx Corporation have?
OptimizeRx Corporation has 18,835,950 shares outstanding.
What happened to OptimizeRx Corporation’s price movement after its last earnings report?
OptimizeRx Corporation reported an EPS of $0.16 in its last earnings report, beating expectations of $0.111. Following the earnings report the stock price went up 24.716%.
Which hedge fund is a major shareholder of OptimizeRx Corporation?
Currently, no hedge funds are holding shares in OPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OptimizeRx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.00 (65.39% Upside)
$13.00 (65.39% Upside)
Blogger Sentiment
Bullish
OPRX Sentiment 75%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 201.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-56.00%
12-Months-Change
Fundamentals
Return on Equity
3.60%
Trailing 12-Months
Asset Growth
-2.92%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
OptimizeRx Corporation
OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell in 2006 and is headquartered in Waltham, MA.
OPRX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: the company delivered an operational beat in Q2, demonstrated margin expansion, launched meaningful product innovations and improved cash/debt metrics, but faced a sizable 30% YoY revenue decline, a dip in net revenue retention to 90%, GAAP loss, and concentration/timing risks tied to a few large customers. Management reiterated full-year guidance and highlighted multiple levers (product launches, mid-market growth, margin optimization, debt reduction) to drive recovery, yet near-term visibility remains uncertain.View all OPRX earnings summariesOPRX Stock 12 Month Forecast
Average Price Target
$13.00
▲(65.39% Upside)
Technical Analysis
Ownership Overview
7.80% Insiders
15.27% Mutual Funds
0.45% Other Institutional Investors
70.04% Public Companies and
Individual Investors